Clinical Trials Logo

Refractory Non-Hodgkin Lymphoma clinical trials

View clinical trials related to Refractory Non-Hodgkin Lymphoma.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 3

NCT ID: NCT02568553 Active, not recruiting - Clinical trials for Recurrent Mantle Cell Lymphoma

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Start date: November 15, 2016
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of lenalidomide and blinatumomab when given together in treating patients with non-Hodgkin lymphoma that has returned after a period of improvement (relapsed). Biological therapies, such as lenalidomide, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Blinatumomab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.

NCT ID: NCT01811368 Active, not recruiting - Clinical trials for Relapsed Non Hodgkin Lymphoma

Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Start date: March 12, 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well ibritumomab tiuxetan before donor peripheral blood stem cell transplant works in treating patients with relapsed or refractory non-Hodgkin lymphoma. Giving rituximab, antithymocyte globulin, and total-lymphoid irradiation (TLI) before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem cells. Also, radiolabeled monoclonal antibodies, such as ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving rituximab, antithymocyte globulin, and TLI before the transplant together with cyclosporine and mycophenolate mofetil after the transplant may stop this from happening. Giving a radiolabeled monoclonal antibody before a donor peripheral blood stem cell transplant may be an effective treatment for non-Hodgkin lymphoma.

NCT ID: NCT01619761 Active, not recruiting - Clinical trials for Myelodysplastic Syndrome

NK Cells in Cord Blood Transplantation

Start date: May 3, 2013
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best way to give natural killer cells and donor umbilical cord blood transplant in treating patients with hematological malignancies. Giving chemotherapy with or without total body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells and natural killer cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.